Therefore, despite the difficulties in targeting a hidden target and the huge implications of its absence, viable strategies have been indicated and the subsequent deeper research means that some of them could really be a breakthrough for patients with LKB1-mutated NSCLC. The gene discussed is STK11; the disease is non-small cell lung carcinoma.